US Oncology, Inc. Research Affiliated Physicians to Present at 2011 American Society of Clinical Oncology Annual Meeting
THE WOODLANDS, Texas, May 26, 2011 /PRNewswire/ -- McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, announced today that four physicians affiliated with US Oncology Research and the United Network of US Oncology will give oral presentations at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 3 - 7 at McCormick Place in Chicago.
ASCO is the world's leading professional organization representing physicians who care for people with cancer. More than 70 McKesson Specialty Care Solutions | US Oncology affiliated oncology experts have contributed to more than 60 studies being featured at this year's major medical meeting.
"US Oncology Research affiliated investigators are consistently on the cutting edge when it comes to the life-changing therapies of the future," said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2011 ASCO Annual Meeting. "When it comes to advancing cancer care, these investigators are contributing in a major way. Take the MEK inhibitor study for example. The investigators understand molecular mechanisms, work with companies which have drugs targeting those mechanisms and use them to successfully treat patients in their practices. This is translational research at its best."
The four studies being presented orally at ASCO by US Oncology Research affiliated physicians are as follows: | ||
Sunday, June 5, 9:45 AM - 10:00 AM, Hall B1 | ||
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. | ||
John Pippen, MD, FACP, Texas Oncology | ||
Sunday, June 5, 4:30 PM - 4:45 PM, Hall B1 | ||
Randomized, phase III study of adjuvant doxorubicin + cyclophosphamide (AC) --> docetaxel (T) +/- capecitabine (X), in high-risk EBC: Exploratory Ki-67 analyses. | ||
Joyce O'Shaughnessy, MD, Texas Oncology | ||
Monday, June 6, 11:00 AM - 11:15 AM, Hall B1 | ||
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). | ||
Robert Jotte, MD, PhD, Rocky Mountain Cancer Centers | ||
Tuesday, June 7, 8:00 AM - 8:15 AM, Arie Crown Theater | ||
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). | ||
"Studies such as these are leading to advances in treating cancer," said John Pippen, MD, FACP, Texas Oncology. "Our US Oncology clinical trials lead to approval of new drugs, better treatment combinations, and better prediction of whether a patient will benefit from a particular cancer treatment."
In addition to these oral presentations, Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology, will be speaking during an education session on the management of unique subsets of patients with renal cell cancer. This session takes place on Sunday, June 5 in Hall D2 from 11:30 AM 12:45 PM.
US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.
Other presentations that McKesson Specialty Care Solutions | US Oncology affiliated investigators are part of include:
Oral Presentations: | ||
Thomas Cartwright, MD, Ocala Oncology Center | ||
Saturday, June 4, 2:45 PM 3:00 PM, Hall D1 | ||
A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. | ||
Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology | ||
Saturday, June 4, 4:00 PM 4:15 PM, Arie Crown Theater | ||
BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. | ||
Michael Teneriello, MD, FACOG, Texas Oncology | ||
Saturday, June 4, 4:15 PM - 4:30 PM, E354a | ||
OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). | ||
Jerome Goldschmidt, MD, Blue Ridge Cancer Care | ||
Sunday, June 5, 10:00 AM - 10:15 AM, Hall D1 | ||
Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with Erlotinib in advanced NSCLC. | ||
Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research | ||
Sunday, June 5, 11:00 AM - 11:15 AM, Arie Crown Theater | ||
Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. | ||
Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology | ||
Sunday, June 5, 11:50 AM - 12:10 PM, Hall D2 | ||
Management of Unique Subsets of Patients with Renal Cell Cancer. | ||
Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada | ||
Alexander Spira, MD, Virginia Cancer Specialists | ||
Sunday, June 5, 12:00 PM - 12:15 PM, Arie Crown Theater | ||
Cabozantinib (XL184) has activity in both soft tissue & bone: Results of a phase 2 randomized discontinuation trial (RDT) in patients (pts) w/ advanced solid tumors. | ||
Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology | ||
Monday, June 6, 8:00 AM - 8:15 AM, Hall D2 | ||
Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. | ||
Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center | ||
Donald Richards, MD, PhD, Texas Oncology | ||
Monday, June 6, 9:30 AM - 12:30 PM, Arie Crown Theater | ||
Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. | ||
Alexander Spira, MD, Virginia Cancer Specialists | ||
Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada | ||
Monday, June 6, 1:15 PM - 1:30 PM, Hall D1 | ||
Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. | ||
Poster Discussions: | |||
Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research | |||
Poster #23 | Saturday, June 4, 8:00 AM 12:00 PM, S403 | ||
Discussion | 12:00 PM 1:00 PM, S406 | ||
Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. | |||
Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research | |||
Poster #5 | Saturday, June 4, 2:00 PM - 6:00 PM, S403 | ||
Discussion | 5:00 PM - 6:00 PM, S406 | ||
Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. | |||
Guru Sonpavde, MD, Texas Oncology | |||
Mark Fleming, MD, Virginia Oncology Associates | |||
Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology | |||
Poster #8 | Saturday, June 4, 2:00 PM - 6:00 PM, E450a | ||
Discussion | 5:00 PM - 6:00 PM, Hall D | ||
A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC). | |||
Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology | |||
Poster #17 | Saturday, June 4, 2:00 PM - 6:00 PM, S103 | ||
Discussion | 5:00 PM - 6:00 PM, S100bc | ||
Circulating protein biomarkers of sunitinib and interferon efficacy in treatment naive patients with metastatic renal cell carcinoma. | |||
Carlos Becerra, MD, Texas Oncology | |||
Poster #14 | Monday, June 6, 8:00 AM - 12:00 PM, E450b | ||
Discussion | 11:30 AM - 12:30 PM, Hall D1 | ||
Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). | |||
Donald Richards, MD, PhD, Texas Oncology | |||
Darren M Kocs, MD, Texas Oncology | |||
Alexander Spira, MD, Virginia Cancer Specialists | |||
David McCollum, MD, Texas Oncology | |||
Kristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD, US Oncology Research | |||
Poster #8 | Monday, June 6, 2:00 PM - 6:00 PM, E450b | ||
Discussion | 5:00 PM - 6:00 PM, Hall D1 | ||
Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma; results of a randomized phase II study. | |||
Donald Richards, MD, PhD, Texas Oncology | |||
Poster #11 | Monday, June 6, 2:00 PM - 6:00 PM, E450b | ||
Discussion | 5:00 PM - 6:00 PM, Hall D1 | ||
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. | |||
Guru Sonpavde, MD, Texas Oncology | |||
Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada | |||
Peter Rosen, MD, Roy & Patricia Disney Cancer Research Center | |||
Alexander Spira, MD, Virginia Cancer Specialists | |||
Poster #22 | Tuesday, June 7, 8:00 AM - 12:00 PM, E450b | ||
Discussion | 11:30 AM - 12:30 PM, E354a | ||
Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). | |||
Posters: | |||
Joyce O'Shaughnessy, MD, Texas Oncology | |||
Thomas Cartwright, MD, Ocala Oncology Center | |||
Poster #21C | Saturday, June 4, 8:00 AM - 12:00 PM, Hall A | ||
Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer. | |||
Joe Stephenson, MD, Cancer Centers of t
| |||